Developer docs
API playgroundTry for free, no card

Search company profiles

OM1

Full company profile

uuid00007b3

Namestring
OM1
Legal namestring
OM1, Inc.
Websiteurl
om1.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

OM1 is a Boston-based, privately held healthcare technology company founded in 2015 by Dr. Rich Gliklich that operates a vertically integrated AI platform for generating regulatory-grade real-world evidence (RWE). Its core technology is the patented PhenOM® foundation model — trained on over 1 billion patient-years of longitudinal data spanning 350M+ patients, 1.8M providers, and 90% claims linkage — paired with an Agentic Health Data Framework that uses LLMs, NLP, and machine learning to automate data capture, processing, and enrichment across structured and unstructured EMR, claims, labs, patient-reported outcomes, and social determinants of health. The platform has produced nine validated AI-extracted clinical endpoints (e.g., ePHQ-9, eCDAI, eSLEDAI) used in successful FDA submissions, including the largest AI-processed RWE study supporting Hologic's Aptima HPV Assay label expansion in February 2026.

The company's commercial model combines subscription-based licensing of its Real-World Data Cloud and PhenOM API, usage-based AI prediction services, fee-based clinical registries and automated studies (300+ delivered), and professional scientific/consulting services. OM1 serves three primary customer segments: life sciences companies (Amgen, Abbvie, GSK, Johnson & Johnson, Novartis, Hologic), providers and health systems, and payers — with a quote-based enterprise sales motion supplemented by an API-first distribution channel and European operations led from Switzerland. Its 130+ peer-reviewed publications, 10+ AI patents, and authorship of AHRQ's Registries for Evaluating Patient Outcomes reference text create defensible differentiation in a market competing with Aetion, Flatiron/Roche, IQVIA, and PAREXEL.

Short descriptiontext

OM1 is a Boston-based healthcare AI company that runs the PhenOM® foundation model on 1B+ patient-years of real-world data to deliver regulatory-grade evidence, patient finding, and AI-extracted clinical endpoints to life sciences companies, providers, and payers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
real-world evidence, healthcare AI platform, clinical data analytics, patient outcomes prediction, clinical registry software
Industry2 codes
PRIMARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Software Publishers5132
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
Product category
Healthcare Real-World Evidence Analytics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Enterprise Platform Subscriptions / Data Licensing
TypeSubscription Recurring
Description

Recurring access to OM1's Real-World Data Cloud (350M+ patients), curated datasets, PhenOM API, and AI platform for life sciences, providers, and payers. Customers license cohorts and use the platform for ongoing evidence generation.

om1.com
2Clinical Registries and Automated Studies
TypeProfessional Services
Description

Fee-based prospective and retrospective study programs, including product/disease registries, post-approval safety/effectiveness studies (PASS/PAES), long-term follow-up, and rare disease programs; delivered via 300+ registry/study engagements.

om1.com
3Scientific & Consulting Services
TypeProfessional Services
Description

Project-based RWE studies, rapid insights/feasibility analytics, and regulatory and payer strategy consulting delivered by OM1's in-house epidemiologists, biostatisticians, and data scientists.

om1.com
4Patient Finding and Outcomes Prediction (PhenOM API)
TypeUsage Based
Description

API-driven delivery of patient finding, subtyping, medical events prediction, and treatment response predictions; 200,000 predictions available with results deliverable via API, applications, EHR integration, or reports.

om1.com
5Data Monetization / Cohorts
TypeData Monetisation
Description

License of curated, AI-enriched disease-area and custom cohorts (e.g., Alzheimer's, Depression, Heart Failure, Psoriasis) from the OM1 Real-World Data Cloud with linked EMR, claims, and specialty network data.

om1.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based enterprise engagement
ModelOther
Notes

Not publicly disclosed; Book a Demo required.

om1.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1PhenOM®
Description

OM1's patented AI foundation model for healthcare, trained on over 1 billion patient-years, used for digital phenotyping, subtyping, and prediction of medical events, risks, and treatment outcomes.

om1.com
+5 more records
Core offering1 text field

OM1 builds and operates an AI-powered real-world evidence platform centered on its patented PhenOM® foundation model, trained on over 1 billion patient-years of linked clinical data. The company sells access to its Real-World Data Cloud (350M+ patients), AI-driven patient finding and outcomes prediction, automated clinical registries, curated disease datasets, and scientific consulting services to life sciences companies, healthcare providers, and payers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

OM1 is a platform-plus-modules architecture centered on its patented PhenOM® Foundation Model (trained on over 1 billion patient-years of healthcare data) and the Agentic Health Data Framework. Together, these power OM1's solution modules: (1) Patient Finding & Outcomes Prediction for digital phenotyping and predictive analytics; (2) Clinical Registries and Automated Studies covering 300+ registries with agentic data collection, including PASS/PAES, LTFU, and rare disease programs; (3) Clinical Datasets & Insights backed by the OM1 Real-World Data Cloud (350M+ patients, 90% linked to claims); and (4) Scientific & Consulting Services supported by the Registry Center of Excellence. The PhenOM API exposes these capabilities for partner and developer use. Specialized applications include the Joint Insights™ AI decision support tool (co-developed with Dell Medical School) and the OM1 Patient Finder for rare disease identification. All products leverage OM1's validated NLP/LLM extraction and AI-estimated clinical endpoints (e.g., ePHQ-9, eCDAI, eSLEDAI) used in successful regulatory submissions.

Product and service10 records
1PhenOM® Foundation Model
CategoryCore AI Platform
Description

Patented AI foundation model trained on 1B+ patient-years of real-world healthcare data, used for digital phenotyping, subtyping, patient finding, and prediction of medical events, risks, and treatment outcomes. Sold as a licensed AI platform to life sciences companies, providers, and payers.

2Agentic Health Data Framework
CategoryCore Platform Module
Description

Automation framework that orchestrates AI agents to capture, process, and enrich real-world clinical data, supporting faster and more reliable study execution, registry data collection, and dataset enrichment.

3Patient Finding and Outcomes Prediction
CategorySolution Module
Description

Solution module built on PhenOM® that accelerates patient finding for undiagnosed conditions, predicts disease progression and adverse events, estimates treatment response, and forecasts outcomes. Includes Patient Finding, Subtyping & Segmentation, Medical Events & Outcomes Prediction, and Treatment Response capabilities.

4Clinical Registries and Automated Studies
CategorySolution Module
Description

Solution module delivering 300+ registries and observational studies with agentic data collection and processing, including product/disease registries, post-approval safety/effectiveness studies (PASS/PAES), long-term follow-up, and rare disease programs.

5Clinical Datasets and Insights
CategorySolution Module
Description

Curated, AI-enriched clinical and real-world datasets covering 350M+ patients with 10-year median follow-up, integrating structured and unstructured data (EMR, clinical notes, claims, labs, PROs, social determinants). Includes disease-area datasets and Cohort Explorer dashboards licensed to customers.

6Scientific and Consulting Services
CategoryProfessional Services
Description

Expert consulting in data science, epidemiology, AI, and regulatory strategy, including RWE Studies, Rapid Insights analytics, and Regulatory and Payer Strategy services, supported by 130+ publications across 10+ therapeutic areas.

7Joint Insights™
CategoryAI Decision Support Application
Description

AI-powered clinical decision support tool co-developed with Dell Medical School, powered by PhenOM®, that improves treatment decision quality and patient outcomes for knee osteoarthritis patients.

8OM1 Patient Finder
CategoryAI Application
Description

Proprietary AI tool that identifies patterns in medical histories signaling undiagnosed disease, including rare disease identification. Achieved AUC of 0.82 in case studies with 20x positive patients in the riskiest 1% of the population.

9OM1 Real-World Data Cloud
CategoryData Platform
Description

Cloud-based real-world data platform covering 350M+ patients with 90% linked to claims, 1.8M providers represented, and 10-year median follow-up. HIPAA-compliant, de-identified datasets licensed for AI model training, validation, and evidence generation.

10OM1 Registry Center of Excellence
CategoryAdvisory Service
Description

Strategic consultation, scientific oversight, and data quality expertise for the design, planning, and execution of registry and prospective observational study programs, led by senior editors of AHRQ's Registries for Evaluating Patient Outcomes.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-10
Description

Co-developed Joint Insights™, an AI-powered decision support tool for knee osteoarthritis. A Lancet-published clinical trial demonstrated improved treatment decision quality and patient outcomes; the work builds on the earlier JAMA Network Open RCT (2021).

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Long-term strategic collaboration: Hologic partnered with OM1 to develop a large-scale, automated patient registry for digital breast tomosynthesis vs. digital mammography screening (1.1M women enrolled, 2.5M screenings, 5 large U.S. health systems, 63 imaging facilities). Joint work extended to support FDA approval of Hologic's Aptima HPV Assay in February 2026 based on 650,000+ patient real-world evidence study using OM1's AI platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnered with the American Academy of Dermatology (AAD) and OM1 to use PhenOM® AI to enhance diagnosis and treatment for patients with hidradenitis suppurativa (HS).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnered with Novartis and OM1 to use PhenOM® AI to enhance diagnosis and treatment for hidradenitis suppurativa patients.

530+ Centers of Excellence (GPP)
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Multi-center prospective study in Generalized Pustular Psoriasis (GPP) engaging 30+ Centers of Excellence and 'referral-only sites' over 3 years, with an OM1 central site responsible for clinical outcomes assessments.

om1.com
65 Large U.S. Health Systems (breast cancer screening)
Strategic tierCoreTypeTechnology or Integration
Description

Partner health systems and 63 imaging facilities provided EMR, radiology information systems, and tumor registry data integrated into OM1's common data model for the breast cancer screening registry with Hologic.

om1.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest global RWE, clinical research, and healthcare data analytics provider. Comparable to OM1 as a buyer and operator of large-scale real-world data, registries, and post-approval studies, but with materially broader scale and a non-AI-native stack.

TypeDirect peer
Description

Real-world evidence analytics platform serving life sciences with regulatory-grade evidence generation for market access and safety. Direct peer to OM1's life sciences RWE offering, with comparable enterprise GTM and FDA-facing positioning.

TypeDirect peer
Description

Oncology-focused real-world data and clinical research platform acquired by Roche. Highly comparable to OM1's disease-specific AI data and registry capabilities, with deep regulatory and pharma partnerships.

4Tempus AI
TypeDirect peer
Description

AI-driven precision medicine company combining multi-modal clinical and molecular data for life sciences and providers. Comparable to OM1 on the AI foundation model plus healthcare data cloud thesis, with overlap in life sciences and clinical decision support.

TypeEmerging player
Description

AI SaaS company for oncology RWE and clinical research, with curated real-world data and AI applications for pharma. Comparable to OM1's specialty RWE and AI decision support offerings in oncology and adjacent therapeutic areas.

TypeBroad incumbent
Description

Healthcare data and analytics provider built on top of large EHR installed base, including life sciences research-grade datasets. Overlaps with OM1's Real-World Data Cloud and clinical datasets offering for life sciences and providers.

TypeBroad incumbent
Description

Largest US healthcare data and analytics franchise, integrating claims, EHR, and pharmacy data. Comparable to OM1 on real-world data scale and payer/provider analytics, but with vastly broader assets and a non-API-first commercial model.

TypeBroad incumbent
Description

Global CRO and RWE services provider following the PRA Health Sciences merger. Comparable to OM1 in registries, post-marketing studies, and RWE consulting for life sciences, with broader clinical operations scale.

TypeBroad incumbent
Description

Clinical trials and real-world data platform for life sciences, with synthetic control arms and RWE analytics. Overlaps with OM1's automated studies and AI-driven evidence generation, particularly in clinical development.

TypeEmerging player
Description

Health data connectivity and de-identification layer enabling linkage across data sources. Comparable to OM1's linked EMR/claims/specialty network data cloud and supports similar life sciences and provider use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers15 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OM1

Healthcare Real-World Evidence Analyticsom1.com

OM1 is a Boston-based healthcare AI company that runs the PhenOM® foundation model on 1B+ patient-years of real-world data to deliver regulatory-grade evidence, patient finding, and AI-extracted clinical endpoints to life sciences companies, providers, and payers.

What OM1 does

OM1 is a Boston-based, privately held healthcare technology company founded in 2015 by Dr. Rich Gliklich that operates a vertically integrated AI platform for generating regulatory-grade real-world evidence (RWE). Its core technology is the patented PhenOM® foundation model — trained on over 1 billion patient-years of longitudinal data spanning 350M+ patients, 1.8M providers, and 90% claims linkage — paired with an Agentic Health Data Framework that uses LLMs, NLP, and machine learning to automate data capture, processing, and enrichment across structured and unstructured EMR, claims, labs, patient-reported outcomes, and social determinants of health. The platform has produced nine validated AI-extracted clinical endpoints (e.g., ePHQ-9, eCDAI, eSLEDAI) used in successful FDA submissions, including the largest AI-processed RWE study supporting Hologic's Aptima HPV Assay label expansion in February 2026.

The company's commercial model combines subscription-based licensing of its Real-World Data Cloud and PhenOM API, usage-based AI prediction services, fee-based clinical registries and automated studies (300+ delivered), and professional scientific/consulting services. OM1 serves three primary customer segments: life sciences companies (Amgen, Abbvie, GSK, Johnson & Johnson, Novartis, Hologic), providers and health systems, and payers — with a quote-based enterprise sales motion supplemented by an API-first distribution channel and European operations led from Switzerland. Its 130+ peer-reviewed publications, 10+ AI patents, and authorship of AHRQ's Registries for Evaluating Patient Outcomes reference text create defensible differentiation in a market competing with Aetion, Flatiron/Roche, IQVIA, and PAREXEL.

OM1 firmographics

Firmographics
Name
OM1
Legal name
OM1, Inc.
Website
https://om1.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
OM1 is a Boston-based healthcare AI company that runs the PhenOM® foundation model on 1B+ patient-years of real-world data to deliver regulatory-grade evidence, patient finding, and AI-extracted clinical endpoints to life sciences companies, providers, and payers.
Ownership category
akta.pro rank

OM1 industry classification

Industry
Product category
Healthcare Real-World Evidence Analytics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Software Publishers (5132)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Real-world evidence
  • Healthcare AI platform
  • Clinical data analytics
  • Patient outcomes prediction
  • Clinical registry software

Where OM1 is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

OM1 business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Enterprise Platform Subscriptions / Data Licensing: Recurring access to OM1's Real-World Data Cloud (350M+ patients), curated datasets, PhenOM API, and AI platform for life sciences, providers, and payers. Customers license cohorts and use the platform for ongoing evidence generation.
  2. Clinical Registries and Automated Studies: Fee-based prospective and retrospective study programs, including product/disease registries, post-approval safety/effectiveness studies (PASS/PAES), long-term follow-up, and rare disease programs; delivered via 300+ registry/study engagements.
  3. Scientific & Consulting Services: Project-based RWE studies, rapid insights/feasibility analytics, and regulatory and payer strategy consulting delivered by OM1's in-house epidemiologists, biostatisticians, and data scientists.
  4. Patient Finding and Outcomes Prediction (PhenOM API): API-driven delivery of patient finding, subtyping, medical events prediction, and treatment response predictions; 200,000 predictions available with results deliverable via API, applications, EHR integration, or reports.
  5. Data Monetization / Cohorts: License of curated, AI-enriched disease-area and custom cohorts (e.g., Alzheimer's, Depression, Heart Failure, Psoriasis) from the OM1 Real-World Data Cloud with linked EMR, claims, and specialty network data.

Pricing tiers

ModelBillingPrice
Other—Quote-based enterprise engagement

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

OM1 product offering

Product offering

Core offering

OM1 builds and operates an AI-powered real-world evidence platform centered on its patented PhenOM® foundation model, trained on over 1 billion patient-years of linked clinical data. The company sells access to its Real-World Data Cloud (350M+ patients), AI-driven patient finding and outcomes prediction, automated clinical registries, curated disease datasets, and scientific consulting services to life sciences companies, healthcare providers, and payers.

Product overview

OM1 is a platform-plus-modules architecture centered on its patented PhenOM® Foundation Model (trained on over 1 billion patient-years of healthcare data) and the Agentic Health Data Framework. Together, these power OM1's solution modules: (1) Patient Finding & Outcomes Prediction for digital phenotyping and predictive analytics; (2) Clinical Registries and Automated Studies covering 300+ registries with agentic data collection, including PASS/PAES, LTFU, and rare disease programs; (3) Clinical Datasets & Insights backed by the OM1 Real-World Data Cloud (350M+ patients, 90% linked to claims); and (4) Scientific & Consulting Services supported by the Registry Center of Excellence. The PhenOM API exposes these capabilities for partner and developer use. Specialized applications include the Joint Insights™ AI decision support tool (co-developed with Dell Medical School) and the OM1 Patient Finder for rare disease identification. All products leverage OM1's validated NLP/LLM extraction and AI-estimated clinical endpoints (e.g., ePHQ-9, eCDAI, eSLEDAI) used in successful regulatory submissions.

Differentiator

Problem solved

Functional benefit

Brands

  • PhenOM®: OM1's patented AI foundation model for healthcare, trained on over 1 billion patient-years, used for digital phenotyping, subtyping, and prediction of medical events, risks, and treatment outcomes.
  • Joint Insights™
  • OM1 Patient Finder
  • OM1 Real-World Data Cloud
  • OM1 Registry Center of Excellence
  • PremiOM™

Products and services

  • PhenOM® Foundation Model Patented AI foundation model trained on 1B+ patient-years of real-world healthcare data, used for digital phenotyping, subtyping, patient finding, and prediction of medical events, risks, and treatment outcomes. Sold as a licensed AI platform to life sciences companies, providers, and payers.
  • Agentic Health Data Framework Automation framework that orchestrates AI agents to capture, process, and enrich real-world clinical data, supporting faster and more reliable study execution, registry data collection, and dataset enrichment.
  • Patient Finding and Outcomes Prediction Solution module built on PhenOM® that accelerates patient finding for undiagnosed conditions, predicts disease progression and adverse events, estimates treatment response, and forecasts outcomes. Includes Patient Finding, Subtyping & Segmentation, Medical Events & Outcomes Prediction, and Treatment Response capabilities.
  • Clinical Registries and Automated Studies Solution module delivering 300+ registries and observational studies with agentic data collection and processing, including product/disease registries, post-approval safety/effectiveness studies (PASS/PAES), long-term follow-up, and rare disease programs.
  • Clinical Datasets and Insights Curated, AI-enriched clinical and real-world datasets covering 350M+ patients with 10-year median follow-up, integrating structured and unstructured data (EMR, clinical notes, claims, labs, PROs, social determinants). Includes disease-area datasets and Cohort Explorer dashboards licensed to customers.
  • Scientific and Consulting Services Expert consulting in data science, epidemiology, AI, and regulatory strategy, including RWE Studies, Rapid Insights analytics, and Regulatory and Payer Strategy services, supported by 130+ publications across 10+ therapeutic areas.
  • Joint Insights™ AI-powered clinical decision support tool co-developed with Dell Medical School, powered by PhenOM®, that improves treatment decision quality and patient outcomes for knee osteoarthritis patients.
  • OM1 Patient Finder Proprietary AI tool that identifies patterns in medical histories signaling undiagnosed disease, including rare disease identification. Achieved AUC of 0.82 in case studies with 20x positive patients in the riskiest 1% of the population.
  • OM1 Real-World Data Cloud Cloud-based real-world data platform covering 350M+ patients with 90% linked to claims, 1.8M providers represented, and 10-year median follow-up. HIPAA-compliant, de-identified datasets licensed for AI model training, validation, and evidence generation.
  • OM1 Registry Center of Excellence Strategic consultation, scientific oversight, and data quality expertise for the design, planning, and execution of registry and prospective observational study programs, led by senior editors of AHRQ's Registries for Evaluating Patient Outcomes.

Companies that use OM1

Customer profile

Named customers15 records

Segments3 records

Ideal customer profiles3 records

OM1 technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature8 records

OM1 partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • Dell Medical School (The University of Texas at Austin)coreStrategic or Co-development Partner · 10 December 2025Co-developed Joint Insights™, an AI-powered decision support tool for knee osteoarthritis. A Lancet-published clinical trial demonstrated improved treatment decision quality and patient outcomes; the work builds on the earlier JAMA Network Open RCT (2021).
  • HologicflagshipStrategic or Co-development Partner · 1 January 2018Long-term strategic collaboration: Hologic partnered with OM1 to develop a large-scale, automated patient registry for digital breast tomosynthesis vs. digital mammography screening (1.1M women enrolled, 2.5M screenings, 5 large U.S. health systems, 63 imaging facilities). Joint work extended to support FDA approval of Hologic's Aptima HPV Assay in February 2026 based on 650,000+ patient real-world evidence study using OM1's AI platform.
  • NovartiscoreStrategic or Co-development PartnerPartnered with the American Academy of Dermatology (AAD) and OM1 to use PhenOM® AI to enhance diagnosis and treatment for patients with hidradenitis suppurativa (HS).
  • American Academy of Dermatology (AAD)coreStrategic or Co-development PartnerPartnered with Novartis and OM1 to use PhenOM® AI to enhance diagnosis and treatment for hidradenitis suppurativa patients.
  • 30+ Centers of Excellence (GPP)coreImplementation/ SI/ Consulting PartnerMulti-center prospective study in Generalized Pustular Psoriasis (GPP) engaging 30+ Centers of Excellence and 'referral-only sites' over 3 years, with an OM1 central site responsible for clinical outcomes assessments.
  • 5 Large U.S. Health Systems (breast cancer screening)coreTechnology or IntegrationPartner health systems and 63 imaging facilities provided EMR, radiology information systems, and tumor registry data integrated into OM1's common data model for the breast cancer screening registry with Hologic.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

OM1 competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: Largest global RWE, clinical research, and healthcare data analytics provider. Comparable to OM1 as a buyer and operator of large-scale real-world data, registries, and post-approval studies, but with materially broader scale and a non-AI-native stack.
  • Veradigm (formerly Allscripts): Healthcare data and analytics provider built on top of large EHR installed base, including life sciences research-grade datasets. Overlaps with OM1's Real-World Data Cloud and clinical datasets offering for life sciences and providers.
  • Optum (UnitedHealth Group): Largest US healthcare data and analytics franchise, integrating claims, EHR, and pharmacy data. Comparable to OM1 on real-world data scale and payer/provider analytics, but with vastly broader assets and a non-API-first commercial model.
  • ICON plc: Global CRO and RWE services provider following the PRA Health Sciences merger. Comparable to OM1 in registries, post-marketing studies, and RWE consulting for life sciences, with broader clinical operations scale.
  • Medidata Solutions (Dassault Systèmes): Clinical trials and real-world data platform for life sciences, with synthetic control arms and RWE analytics. Overlaps with OM1's automated studies and AI-driven evidence generation, particularly in clinical development.

Direct peers

  • Aetion: Real-world evidence analytics platform serving life sciences with regulatory-grade evidence generation for market access and safety. Direct peer to OM1's life sciences RWE offering, with comparable enterprise GTM and FDA-facing positioning.
  • Flatiron Health: Oncology-focused real-world data and clinical research platform acquired by Roche. Highly comparable to OM1's disease-specific AI data and registry capabilities, with deep regulatory and pharma partnerships.
  • Tempus AI: AI-driven precision medicine company combining multi-modal clinical and molecular data for life sciences and providers. Comparable to OM1 on the AI foundation model plus healthcare data cloud thesis, with overlap in life sciences and clinical decision support.

Emerging players

  • ConcertAI: AI SaaS company for oncology RWE and clinical research, with curated real-world data and AI applications for pharma. Comparable to OM1's specialty RWE and AI decision support offerings in oncology and adjacent therapeutic areas.
  • Datavant: Health data connectivity and de-identification layer enabling linkage across data sources. Comparable to OM1's linked EMR/claims/specialty network data cloud and supports similar life sciences and provider use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

OM1 social profiles

Digital presence

OM1 compliance and trust

Trust signal

Compliance3 records

OM1 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OM1 leadership team

Management profile

Number of profiles

Profiles14 records

OM1 subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

OM1 funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OM1 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OM1

What does OM1 do?

OM1 builds and operates an AI-powered real-world evidence platform centered on its patented PhenOM® foundation model, trained on over 1 billion patient-years of linked clinical data. The company sells access to its Real-World Data Cloud (350M+ patients), AI-driven patient finding and outcomes prediction, automated clinical registries, curated disease datasets, and scientific consulting services to life sciences companies, healthcare providers, and payers.

Is OM1 a public or private company?

OM1 is a private company. It is classified as venture growth investor backed and is currently operating.

When was OM1 founded?

OM1 was founded in 2015. It employs 51 to 100 people.

Where is OM1 based?

OM1 is headquartered in Boston, United States, in the North America region.

How does OM1 make money?

Five revenue lines are on record. Enterprise Platform Subscriptions / Data Licensing is the primary driver. The others are clinical Registries and Automated Studies, scientific & Consulting Services, patient Finding and Outcomes Prediction (PhenOM API) and data Monetization / Cohorts.

Who are OM1's main competitors?

Broad incumbents on record are IQVIA, Veradigm (formerly Allscripts), Optum (UnitedHealth Group), ICON plc and Medidata Solutions (Dassault Systèmes). Direct peers are Aetion, Flatiron Health and Tempus AI. Emerging players are ConcertAI and Datavant.

Does OM1 have an API?

Yes. OM1 offers the PhenOM API which enables partners to access extensively enriched real-world data (RWD) and AI capabilities, run predictive insights, and automate data processing. Results from the PhenOM model can be delivered through multiple mechanisms including the API, applications, EHR integration, or delivered reports. Specific API protocols (REST/GraphQL), authentication methods, rate limits, and versioning are not specified in the source.

What industry is OM1 in?

OM1's product category is Healthcare Real-World Evidence Analytics. Its primary akta.pro industry code is HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics), with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BriefglanceAI Powers FDA Nod for HPV Test in Landmark Real-World StudyThe U.S. Food and Drug Administration approved Hologic's Aptima HPV Assay for primary cervical cancer screening in February 2026, based on one of the largest real-world evidence studies ever conducted for a regulatory submission, analyzing data from over 650,000 women across the United States. Boston-based AI company OM1 provided the platform that processed the massive dataset, using machine learning to extract and interpret unstructured clinical data from electronic health records. The landmark study, presented at the Medical Device Innovation Consortium Evidence Summit, sets a new blueprint for using AI-powered real-world evidence to accelerate regulatory approvals for medical technologies.Business Wire BlogOM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic's Aptima HPV AssayOM1, a real-world evidence generation company, presented its role in a landmark FDA approval study for Hologic's Aptima HPV Assay, which was approved for primary cervical cancer screening in February 2026. The study spanned more than 650,000 women across multiple U.S. health systems, making it one of the largest real-world evidence studies ever conducted for an FDA submission. The approval marks a significant implementation case for real-world evidence in regulatory submissions, demonstrating that OM1's automation platform can reduce study constraints without compromising data quality.Business Wire BlogNew Lancet-Published Study Shows AI-Powered Decision Support Tool Improves Decision Quality and Patient OutcomesA randomized clinical trial published in The Lancet's eClinicalMedicine found that Joint Insights, an AI-enabled decision support tool powered by OM1's PhenOM model and co-developed with Dell Medical School at The University of Texas at Austin, significantly improved treatment decision quality and patient outcomes for knee osteoarthritis patients compared to digital education alone. Patients using the tool experienced better medium- and long-term physical function, stronger alignment between treatment choices and personal preferences, and lower decision conflict and regret. The study represents one of the first rigorous randomized trials assessing an AI-enabled decision aid in orthopedics, with potential applications extending beyond orthopedics to physical therapy, behavioral interventions, and lifestyle strategies.Business Wire BlogOM1 Adds 1 Million Patients to Its Mental Health Network, Significantly Expanding Specialty Coverage and Driving New Possibilities for Real-World Research and Personalized CareOM1 announced the expansion of its specialty mental health network by adding over one million patients, establishing it as the largest and most clinically rich network for real-world evidence in this sector. This milestone enhances the company's ability to provide high-quality, representative data to support decision-making in life sciences and healthcare. The expansion leverages AI to extract insights from clinical notes, improving research capabilities for conditions such as major depressive disorder and schizophrenia.BioSpaceOM1 Expands into Europe to Strengthen Support for Life Sciences with AI-Driven Real-World Evidence SolutionsOM1 announced its expansion into Europe to provide AI-driven real-world evidence solutions for pharmaceutical and healthcare organizations. The company aims to enhance support for global life sciences firms in drug development, market access, and regulatory decision-making through its OM1 Aspen and PhenOM platforms.Om1AI and Real-World Evidence: Transforming Pharmaceutical Research and Market AccessAn October 5, 2024 Market Access Today article outlines how generative AI and real-world evidence are reshaping pharmaceutical research and market access, citing a projected 5.9% CAGR from 2023 to 2028. It highlights OM1's machine learning model that estimates Systemic Lupus Erythematosus Disease Activity Index scores from unstructured clinical notes.PR NewswireOM1 Earns Frost & Sullivan's 2024 North American New Product Innovation Award for Transforming Real-world Evidence Analytics Solutions Industry with Its Pioneering AI-powered PlatformsFrost & Sullivan awarded OM1 the 2024 North American New Product Innovation Award for its AI-powered real-world evidence analytics platforms Orion, Lyra, and Polaris. The platforms integrate clinical data to enable patient journey analysis and personalized insights for healthcare providers and researchers.PR NewswireOM1 Earns Frost & Sullivan's 2024 North American New Product Innovation Award for Transforming Real-world Evidence Analytics Solutions Industry with Its Pioneering AI-powered PlatformsFrost & Sullivan awarded OM1 the 2024 North American New Product Innovation Award for its AI-powered real-world evidence analytics platforms. The company's Orion, Lyra, and Polaris solutions integrate multiple data sources to enhance clinical decision-making and research effectiveness. The award recognizes the value-added features and increased ROI for customers.Business Wire BlogOM1, a Pioneer in Patient Registries, Launches Its Registries Center of ExcellenceOM1 launched its Registries Center of Excellence, offering expert consultation on patient registries from concept through analysis. The center supports its Aspen automated study platform and aims to help clients generate regulatory-grade evidence for real-world data submissions. The initiative follows FDA guidance on registries for regulatory decision-making.Om1OM1 Launches Three New Products Powered by Patented AI Platform to Expedite Delivery of Personalized MedicineOM1 announced three new products — OM1 Orion, OM1 Lyra and OM1 Polaris — powered by its PhenOM digital phenotyping platform, which uses AI and real-world evidence to inform patient journeys and clinical research. Orion offers a 360-degree view of disease progression, Lyra stratifies treatment predictions at point of care, and Polaris optimizes trial recruitment. The platform draws on data from over 340 million patients.